Statements (11)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antipsychotic medication
|
| gptkbp:clinicalTrialPhase |
Phase 1
|
| gptkbp:developedBy |
gptkb:Cerevel_Therapeutics
|
| https://www.w3.org/2000/01/rdf-schema#label |
CLP-325
|
| gptkbp:intendedUse |
treatment of schizophrenia
|
| gptkbp:mechanismOfAction |
D1/D5 dopamine receptor partial agonist
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:status |
investigational drug
|
| gptkbp:therapeuticArea |
neuropsychiatric disorders
|
| gptkbp:bfsParent |
gptkb:CLP_series
|
| gptkbp:bfsLayer |
7
|